JILL OLMSTEAD: Open Payments
NPI 1740276732 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,940 in 74 payments from 14 companies in 2025. Trend: 2023 $3,270 · 2024 $11,962 · 2025 $5,940
Consulting: $3,863Food & beverage: $2,078
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 4 | $2,763 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $1,474 |
| ABBVIE INC. | 19 | $354 |
| Madrigal Pharmaceuticals | 9 | $333 |
| Ardelyx, Inc. | 9 | $289 |
| Ipsen Biopharmaceuticals, Inc | 3 | $155 |
| Janssen Biotech, Inc. | 7 | $153 |
| Gilead Sciences, Inc. | 7 | $146 |
| Regeneron Healthcare Solutions, Inc. | 2 | $97 |
| PFIZER INC. | 4 | $73 |
Products named: VOQUEZNA, TRULANCE, REZDIFFRA, IBSRELA, SKYRIZI, RINVOQ, IQIRVO, TREMFYA.
Industry payments across CA — which companies pay providers there.
